Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Semin Thromb Hemost ; 50(6): 817-828, 2024 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-38228166

RESUMO

Persistence of serum antiphospholipid antibodies (aPL) is associated with a high thrombotic risk, both arterial and venous, and with pregnancy complications. Due to the potential morbidity and mortality associated with the presence of aPL, identifying and recognizing risk factors for the development of aPL and thrombosis in aPL carriers may help to prevent and reduce the burden of disease. Multiple elements are involved in the pathomechanism of aPL development and aPL-related thrombosis such as genetics, malignancy, and infections. This review will address the role of both well-known risk factors and their evolution, and of emerging risk factors, including COVID-19, in the development of aPL and thrombosis in aPL carriers.


Assuntos
Anticorpos Antifosfolipídeos , Síndrome Antifosfolipídica , COVID-19 , Humanos , Síndrome Antifosfolipídica/complicações , Síndrome Antifosfolipídica/imunologia , Anticorpos Antifosfolipídeos/sangue , Anticorpos Antifosfolipídeos/imunologia , Fatores de Risco , Feminino , Gravidez , COVID-19/imunologia , COVID-19/complicações , COVID-19/sangue , Trombose/etiologia , Trombose/imunologia , SARS-CoV-2/imunologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA